Do analysts prefer UTMD or QDEL?

QuidelOrtho has a consensus target price of $13.63, indicating a potential upside of 26.51%. Given QuidelOrtho's higher probable upside, analysts clearly believe QuidelOrtho is more favorable than Utah Medical Products. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Utah Medical Products 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 QuidelOrtho 3 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Do analysts prefer UTMD or CERS?

Cerus has a consensus target price of $5.25, suggesting a potential upside of 130.26%. Given Cerus' stronger consensus rating and higher possible upside, analysts clearly believe Cerus is more favorable than Utah Medical Products. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Utah Medical Products 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Cerus 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Do analysts recommend EMBC or UTMD?

Embecta presently has a consensus price target of $11.00, suggesting a potential upside of 94.69%. Given Embecta's higher probable upside, analysts plainly believe Embecta is more favorable than Utah Medical Products. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Embecta 2 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.60 Utah Medical Products 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts recommend SMTI or UTMD?

Sanara MedTech currently has a consensus price target of $35.00, indicating a potential upside of 0.43%. Given Sanara MedTech's higher probable upside, equities analysts plainly believe Sanara MedTech is more favorable than Utah Medical Products. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sanara MedTech 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80 Utah Medical Products 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts prefer UTMD or OSUR?

OraSure Technologies has a consensus target price of $3.00, indicating a potential downside of 24.24%. Given OraSure Technologies' higher possible upside, analysts plainly believe OraSure Technologies is more favorable than Utah Medical Products. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Utah Medical Products 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 OraSure Technologies 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Utah Medical Products (UTMD) Competitors

$74.13 -0.22 (-0.30%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$74.28 +0.16 (+0.21%)

As of 10/2/2026 04:10 PM Eastern

Compare

UTMD vs. QDEL, CERS, EMBC, SMTI, and OSUR

Should you buy Utah Medical Products stock or one of its competitors? Utah Medical Products's main competitors and comparable companies include QuidelOrtho (QDEL), Cerus (CERS), Embecta (EMBC), Sanara MedTech (SMTI), and OraSure Technologies (OSUR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare supplies" industry.

How does Utah Medical Products compare to QuidelOrtho?

Utah Medical Products (NASDAQ:UTMD) and QuidelOrtho (NASDAQ:QDEL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

Utah Medical Products has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market. Comparatively, QuidelOrtho has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market.

69.6% of Utah Medical Products shares are held by institutional investors. Comparatively, 99.0% of QuidelOrtho shares are held by institutional investors. 8.0% of Utah Medical Products shares are held by insiders. Comparatively, 1.1% of QuidelOrtho shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, QuidelOrtho had 1 more articles in the media than Utah Medical Products. MarketBeat recorded 1 mentions for QuidelOrtho and 0 mentions for Utah Medical Products. QuidelOrtho's average media sentiment score of 1.67 beat Utah Medical Products' score of 0.00 indicating that QuidelOrtho is being referred to more favorably in the news media.

Company	Overall Sentiment
Utah Medical Products	Neutral
QuidelOrtho	Very Positive

Utah Medical Products has higher earnings, but lower revenue than QuidelOrtho. QuidelOrtho is trading at a lower price-to-earnings ratio than Utah Medical Products, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Utah Medical Products	$38.52M	6.12	$11.29M	$3.28	22.60
QuidelOrtho	$2.73B	0.27	-$1.13B	-$15.41	N/A

QuidelOrtho has a consensus target price of $13.63, indicating a potential upside of 26.51%. Given QuidelOrtho's higher probable upside, analysts clearly believe QuidelOrtho is more favorable than Utah Medical Products.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Utah Medical Products	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
QuidelOrtho	3 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Utah Medical Products has a net margin of 29.04% compared to QuidelOrtho's net margin of -39.20%. Utah Medical Products' return on equity of 8.74% beat QuidelOrtho's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Utah Medical Products	29.04%	8.74%	8.50%
QuidelOrtho	-39.20%	4.88%	1.63%

Summary

Utah Medical Products beats QuidelOrtho on 9 of the 15 factors compared between the two stocks.

How does Utah Medical Products compare to Cerus?

Utah Medical Products (NASDAQ:UTMD) and Cerus (NASDAQ:CERS) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

Cerus has a consensus target price of $5.25, suggesting a potential upside of 130.26%. Given Cerus' stronger consensus rating and higher possible upside, analysts clearly believe Cerus is more favorable than Utah Medical Products.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Utah Medical Products	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cerus	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Utah Medical Products has higher earnings, but lower revenue than Cerus. Cerus is trading at a lower price-to-earnings ratio than Utah Medical Products, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Utah Medical Products	$38.52M	6.12	$11.29M	$3.28	22.60
Cerus	$206.13M	2.23	-$15.63M	-$0.03	N/A

In the previous week, Cerus had 1 more articles in the media than Utah Medical Products. MarketBeat recorded 1 mentions for Cerus and 0 mentions for Utah Medical Products. Cerus' average media sentiment score of 1.09 beat Utah Medical Products' score of 0.00 indicating that Cerus is being referred to more favorably in the news media.

Company	Overall Sentiment
Utah Medical Products	Neutral
Cerus	Positive

Utah Medical Products has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market. Comparatively, Cerus has a beta of 1.83, indicating that its stock price is 83% more volatile than the broader market.

69.6% of Utah Medical Products shares are owned by institutional investors. Comparatively, 78.4% of Cerus shares are owned by institutional investors. 8.0% of Utah Medical Products shares are owned by insiders. Comparatively, 5.3% of Cerus shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Utah Medical Products has a net margin of 29.04% compared to Cerus' net margin of -3.06%. Utah Medical Products' return on equity of 8.74% beat Cerus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Utah Medical Products	29.04%	8.74%	8.50%
Cerus	-3.06%	-10.19%	-3.14%

Summary

Utah Medical Products and Cerus tied by winning 8 of the 16 factors compared between the two stocks.

How does Utah Medical Products compare to Embecta?

Embecta (NASDAQ:EMBC) and Utah Medical Products (NASDAQ:UTMD) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, risk and dividends.

Embecta has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market. Comparatively, Utah Medical Products has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market.

In the previous week, Embecta had 3 more articles in the media than Utah Medical Products. MarketBeat recorded 3 mentions for Embecta and 0 mentions for Utah Medical Products. Embecta's average media sentiment score of 0.00 equaled Utah Medical Products'average media sentiment score.

Company	Overall Sentiment
Embecta	Neutral
Utah Medical Products	Neutral

93.8% of Embecta shares are owned by institutional investors. Comparatively, 69.6% of Utah Medical Products shares are owned by institutional investors. 1.3% of Embecta shares are owned by company insiders. Comparatively, 8.0% of Utah Medical Products shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Embecta has higher revenue and earnings than Utah Medical Products. Embecta is trading at a lower price-to-earnings ratio than Utah Medical Products, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Embecta	$1.08B	0.30	$95.40M	$1.48	3.82
Utah Medical Products	$38.52M	6.12	$11.29M	$3.28	22.60

Embecta pays an annual dividend of $0.04 per share and has a dividend yield of 0.7%. Utah Medical Products pays an annual dividend of $1.24 per share and has a dividend yield of 1.7%. Embecta pays out 2.7% of its earnings in the form of a dividend. Utah Medical Products pays out 37.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Utah Medical Products has raised its dividend for 3 consecutive years. Utah Medical Products is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Utah Medical Products has a net margin of 29.04% compared to Embecta's net margin of 8.59%. Utah Medical Products' return on equity of 8.74% beat Embecta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Embecta	8.59%	-19.25%	10.82%
Utah Medical Products	29.04%	8.74%	8.50%

Embecta presently has a consensus price target of $11.00, suggesting a potential upside of 94.69%. Given Embecta's higher probable upside, analysts plainly believe Embecta is more favorable than Utah Medical Products.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Embecta	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60
Utah Medical Products	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Utah Medical Products beats Embecta on 9 of the 17 factors compared between the two stocks.

How does Utah Medical Products compare to Sanara MedTech?

Sanara MedTech (NASDAQ:SMTI) and Utah Medical Products (NASDAQ:UTMD) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends.

Sanara MedTech has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market. Comparatively, Utah Medical Products has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market.

Utah Medical Products has lower revenue, but higher earnings than Sanara MedTech. Sanara MedTech is trading at a lower price-to-earnings ratio than Utah Medical Products, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanara MedTech	$103.12M	3.11	-$37.56M	-$3.59	N/A
Utah Medical Products	$38.52M	6.12	$11.29M	$3.28	22.60

In the previous week, Sanara MedTech had 1 more articles in the media than Utah Medical Products. MarketBeat recorded 1 mentions for Sanara MedTech and 0 mentions for Utah Medical Products. Sanara MedTech's average media sentiment score of 0.34 beat Utah Medical Products' score of 0.00 indicating that Sanara MedTech is being referred to more favorably in the media.

Company	Overall Sentiment
Sanara MedTech	Neutral
Utah Medical Products	Neutral

Sanara MedTech currently has a consensus price target of $35.00, indicating a potential upside of 0.43%. Given Sanara MedTech's higher probable upside, equities analysts plainly believe Sanara MedTech is more favorable than Utah Medical Products.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanara MedTech	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Utah Medical Products	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

8.1% of Sanara MedTech shares are owned by institutional investors. Comparatively, 69.6% of Utah Medical Products shares are owned by institutional investors. 42.0% of Sanara MedTech shares are owned by insiders. Comparatively, 8.0% of Utah Medical Products shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Utah Medical Products has a net margin of 29.04% compared to Sanara MedTech's net margin of -29.15%. Sanara MedTech's return on equity of 29.72% beat Utah Medical Products' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanara MedTech	-29.15%	29.72%	2.84%
Utah Medical Products	29.04%	8.74%	8.50%

Summary

Utah Medical Products beats Sanara MedTech on 8 of the 15 factors compared between the two stocks.

How does Utah Medical Products compare to OraSure Technologies?

Utah Medical Products (NASDAQ:UTMD) and OraSure Technologies (NASDAQ:OSUR) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation.

Utah Medical Products has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market. Comparatively, OraSure Technologies has a beta of 1.03, meaning that its share price is 3% more volatile than the broader market.

69.6% of Utah Medical Products shares are owned by institutional investors. Comparatively, 93.5% of OraSure Technologies shares are owned by institutional investors. 8.0% of Utah Medical Products shares are owned by company insiders. Comparatively, 4.7% of OraSure Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Utah Medical Products has higher earnings, but lower revenue than OraSure Technologies. OraSure Technologies is trading at a lower price-to-earnings ratio than Utah Medical Products, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Utah Medical Products	$38.52M	6.12	$11.29M	$3.28	22.60
OraSure Technologies	$115.02M	2.37	-$68.73M	-$0.69	N/A

Utah Medical Products has a net margin of 29.04% compared to OraSure Technologies' net margin of -43.70%. Utah Medical Products' return on equity of 8.74% beat OraSure Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Utah Medical Products	29.04%	8.74%	8.50%
OraSure Technologies	-43.70%	-19.09%	-16.26%

OraSure Technologies has a consensus target price of $3.00, indicating a potential downside of 24.24%. Given OraSure Technologies' higher possible upside, analysts plainly believe OraSure Technologies is more favorable than Utah Medical Products.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Utah Medical Products	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
OraSure Technologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, OraSure Technologies had 2 more articles in the media than Utah Medical Products. MarketBeat recorded 2 mentions for OraSure Technologies and 0 mentions for Utah Medical Products. OraSure Technologies' average media sentiment score of 0.71 beat Utah Medical Products' score of 0.00 indicating that OraSure Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Utah Medical Products	Neutral
OraSure Technologies	Positive

Summary

Utah Medical Products beats OraSure Technologies on 9 of the 15 factors compared between the two stocks.

Get Utah Medical Products News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UTMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

UTMD vs. The Competition

Export

Metric	Utah Medical Products	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$236.02M	$5.48B	$7.15B	$13.28B
Dividend Yield	1.67%	1.81%	2.54%	17.33%
P/E Ratio	22.60	25.42	274.71	26.04
Price / Sales	6.12	67.70	656.46	105.16
Price / Cash	16.61	32.27	78.87	52.62
Price / Book	1.99	5.73	10.93	6.31
Net Income	$11.29M	$152.68M	$3.51B	$362.16M
7 Day Performance	-0.07%	-1.71%	-2.00%	-1.66%
1 Month Performance	4.26%	-4.87%	-6.19%	-4.68%
1 Year Performance	17.11%	1.30%	8.03%	1.57%

Utah Medical Products Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
UTMD Utah Medical Products	0.9427 of 5 stars	$74.13 -0.3%	N/A	+17.1%	$236.02M	$38.52M	22.60	152
QDEL QuidelOrtho	3.028 of 5 stars	$10.60 -2.1%	$13.63 +28.5%	-64.1%	$742.67M	$2.73B	N/A	6,500
CERS Cerus	1.8608 of 5 stars	$2.47 +0.8%	$5.25 +112.6%	+45.2%	$493.74M	$206.13M	N/A	345	News Coverage
EMBC Embecta	3.525 of 5 stars	$5.76 -2.9%	$11.00 +91.0%	-60.5%	$335.99M	$1.08B	3.89	1,850
SMTI Sanara MedTech	0.4115 of 5 stars	$35.09 0.0%	$35.00 -0.3%	+11.7%	$322.50M	$109.81M	N/A	108	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:UTMD) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Utah Medical Products (UTMD) Competitors

UTMD vs. QDEL, CERS, EMBC, SMTI, and OSUR

How does Utah Medical Products compare to QuidelOrtho?

Summary

How does Utah Medical Products compare to Cerus?

Summary

How does Utah Medical Products compare to Embecta?

Summary

How does Utah Medical Products compare to Sanara MedTech?

Summary

How does Utah Medical Products compare to OraSure Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UTMD vs. The Competition

Utah Medical Products Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Utah Medical Products (UTMD) Competitors

UTMD vs. QDEL, CERS, EMBC, SMTI, and OSUR

How does Utah Medical Products compare to QuidelOrtho?

Which has more risk and volatility, UTMD or QDEL?

Do insiders and institutionals believe in UTMD or QDEL?

Does the media refer more to UTMD or QDEL?

Which has stronger earnings & valuation, UTMD or QDEL?

Do analysts prefer UTMD or QDEL?

Is UTMD or QDEL more profitable?

Summary

How does Utah Medical Products compare to Cerus?

Do analysts prefer UTMD or CERS?

Which has preferable earnings and valuation, UTMD or CERS?

Does the media favor UTMD or CERS?

Which has more volatility and risk, UTMD or CERS?

Do institutionals & insiders have more ownership in UTMD or CERS?

Is UTMD or CERS more profitable?

Summary

How does Utah Medical Products compare to Embecta?

Which has more volatility & risk, EMBC or UTMD?

Does the media prefer EMBC or UTMD?

Do institutionals and insiders believe in EMBC or UTMD?

Which has stronger valuation & earnings, EMBC or UTMD?

Is EMBC or UTMD a better dividend stock?

Is EMBC or UTMD more profitable?

Do analysts recommend EMBC or UTMD?

Summary

How does Utah Medical Products compare to Sanara MedTech?

Which has more risk & volatility, SMTI or UTMD?

Which has better earnings and valuation, SMTI or UTMD?

Does the media prefer SMTI or UTMD?

Do analysts recommend SMTI or UTMD?

Do insiders and institutionals have more ownership in SMTI or UTMD?

Is SMTI or UTMD more profitable?

Summary

How does Utah Medical Products compare to OraSure Technologies?

Which has more risk and volatility, UTMD or OSUR?

Do insiders & institutionals have more ownership in UTMD or OSUR?

Which has higher valuation and earnings, UTMD or OSUR?

Is UTMD or OSUR more profitable?

Do analysts prefer UTMD or OSUR?

Does the media favor UTMD or OSUR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UTMD vs. The Competition

Utah Medical Products Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools